PFE  Pfizer Inc.




Consumer Durables


Major Pharmaceuticals

Market Cap.


Vuru Grade


Current Price

+0.07 (+0.20%)

Growth Price

Overvalued by 16.37%

Stability Price

Overvalued by 65.15%

Company Metrics

  • 24.3 P/E
  • 4.27 P/S
  • 3.05 P/B
  • 1.422 EPS
  • 12.30% Cash ROIC
  • 1.67 Cash Ratio
  • 1.06 / 3.07% Dividend
  • 28.37M Avg. Vol.
  • 212.2B Market Cap.

Company Description

Pfizer Inc., a biopharmaceutical company, offers prescription medicines for humans and animals worldwide. The company's Biopharmaceutical segment's provides Lipitor for elevated LDL-cholesterol levels in the blood; Enbrel for rheumatoid arthritis, polyarticular juvenile rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis; Lyrica for post-herpetic neuralgia, diab...

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Pfizer Inc. Wins European Commission Approval For New Prevenar 13 Indication
Bidness ETC - 22 hours ago
Pfizer Inc. (NYSE:PFE) on Tuesday announced that the European Commission has approved an expanded indication for its pneumococcal conjugate vaccine (PCV), Prevenar 13, to prevent pneumonia caused by the 13 pneumococcal serotypes in the ...
Pfizer, Inc. (NYSE:PFE) Update: Pfizer receives orphan status for lung cancer drug - Ashburn Daily
Pfizer gains EU approval for pneumococcal vaccine - Vaccine News Daily
Will Pfizer Inc. Break Up in 2015?
Motley Fool - Feb 10, 2015
Pfizer has been churning out major new products such as its pneumonia and meningitis vaccine, Prevnar-13, during this time period.
Pfizer to pay $17 billion for Hospira Inc. - Allentown Morning Call
Pfizer Inc. Is Not Done With Acquisition Deals Yet - Bidness ETC
Has Pfizer Inc. Finally Solved Its Immuno-oncology Problem?
Motley Fool - Feb 18, 2015
Despite its humble beginnings and numerous setbacks, immunotherapy is on the cusp of becoming a standard part of cancer care, right alongside chemotherapy and surgery.
Interesting June Stock Options for Pfizer
Forbes - Mar 2, 2015
So unless Pfizer Inc sees its shares decline 7.7% and the contract is exercised (resulting in a cost basis of $31.58 per share before broker commissions, subtracting the 42 cents from $32), the only upside to the put seller is from collecting that ...
Pfizer to Buy Hospira for $16 Billion
Wall Street Journal - Feb 5, 2015
Pfizer Inc. said Thursday it would buy smaller rival Hospira Inc. in a $16 billion deal that would transform the New York pharmaceutical company into a leading player in the emerging market for lower-priced knockoffs of costly biotech drugs.
Here's why Pfizer's deal for Hospira has a lot going for it - The Globe and Mail
NICE Okays Pfizer Inc. Inlyta, Rejects Dendreon Corporation Provenge; Bad ...
Bidness ETC - Feb 25, 2015
The National Institute for Health and Care Excellence (NICE) issued two final guidelines today, recommending Pfizer Inc.'s (NYSE:PFE) Inlyta (axitinib) to be used as a second-line treatment option for kidney cancer, while rejecting Dendreon Corporation ...
Which Biotech Stock Should Pfizer, Inc. Buy?
Motley Fool - Feb 8, 2015
Earlier this week, Pfizer announced that it would acquire Hospira, the top provider of injectable drugs. The deal will net Pfizer an intriguing biosimilar program, but some suspect that the company is still hungry for more. If Pfizer is indeed still on ...
Form 4 PFIZER INC For: Feb 27 Filed by: READ IAN C - Mar 2, 2015
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). 1. Name and Address of Reporting Person *. READ IAN C. (Last), (First), (Middle). PFIZER INC.-CORP. SECRETARY. 235 EAST 42ND ST.
Pfizer, Inc., Novartis AG Criticize CDC's Recommendation For Meningitis B ...
Bidness ETC - Feb 27, 2015
Pfizer Inc. (NYSE:PFE) and Novartis AG (ADR) (NYSE:NVS) on Thursday received a green signal from the US Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) for their meningitis B vaccines, for people ...
Pfizer, Novartis say meningitis vaccine scope too narrow - Reuters
5 Things Pfizer, Inc.'s Management Wants You to Know
Motley Fool - Feb 5, 2015
Times are challenging for Pfizer (NYSE: PFE ) , the largest pharmaceutical company in the world by revenue. In its latest quarterly report, Pfizer delivered a 3% decline in revenue to $13.12 billion as foreign currency translation headwinds and patent ...
Pfizer (PFE) Leading In Pre-Market Activity -
Market Update (NYSE:PFE): Pfizer Marks World Cancer Day with Grant to Union ... - Jutia Group